The Silence of the Bioethicists
By Leigh Turner,
Impact Ethics
| 03. 24. 2014
Last week, Kirstin Borgerson, a philosopher at Dalhousie University, published a
thoughtful commentary on my colleague Carl Elliott’s
persistent call for an investigation of Dan Markingson’s death and psychiatric research misconduct at the University of Minnesota. Dan Markingson was a young man from St. Paul who
committed suicide by nearly decapitating himself while enrolled in a psychiatric drug study at the University of Minnesota Medical Center, Fairview.In analyzing the audience’s response to Carl’s public lecture, alongside the typical response of her undergraduate students, Borgerson notes that there was no animated discussion of ethical issues in the Markingson case because “very simply, there is nothing to debate.” Borgerson adds,
Among serious scholars, there is no defense of the practice of: radically violating informed consent …; enrolling suicidal patients in the sort of risky trial that Markingson was enrolled in; having researchers disrespect and disregard concerns raised by family members about the well-being of research subjects during a trial; or creating conditions under which researchers are motivated to enroll subjects so as not to lose out on tens of thousands of...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...